

LITERATURA

- Afanasjev Y. N., Nozdrin V. I., Michalov O. O. et al.: Vlijanije retinoidov na rozvitije i rast experimentalnych opucholej. *Vopr. Onkol.* **29**, 1983, 77.
- Allen S. G., Rodger A., Smyth J. F. et al.: Tamoxifen as primary treatment of breast cancer. *Brit. med. J.* **29**, 1985, 358.
- Amato K. R., Sallan S. E., Jeffrey M.: Combination chemotherapy in relapsed childhood acute leukemia. *Cancer Treat. Rep.* **68**, 1984, 411.
- Anderson R. W.: Risk of handling injectable antineoplastic agents. *Amer. J. Hosp. Pharm.* **39**, 1982, 1881.
- Andrysek O., Dvořák O., Stránská E.: Estimation of sensitivity of human tumours to cytostatics in vitro III. *Neoplasma* **16**, 1969, 239.
- Arnold A.: Anticancer drugs VII. Podophylotoxin derivatives. *Cancer topics*, **5**, 1984, 14.
- Assoian R. K., Grotendorst G. R., Miller D. M. et al.: Cellular transformation by coordinated action of three peptide growth factors from human platelets. *Nature* **309**, 1984, 804.
- Baccarani M., Bosi A., Papa G.: Second malignancy in patients treated for Hodgkin's disease. *Cancer* **46**, 1980, 1735.
- Barré-Sinoussi F., Chermann J. C., Rey T. et al.: Isolation a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). *Science* **220**, 1983, 868.
- Bast R. C., Knapp R. C.: Immunologic approaches to the management of ovarian carcinoma. *Semin. Oncol.* **11**, 1984, 264.
- Begent R. H. J., Begshawe K. D.: The management of high-risk choriocarcinoma. *Semin. Oncol.* **9**, 1982, 198.
- Bek V., Konopásek B., Nový F., et al.: Terapie dřeňových metastáz. *Čas. Lék. čes.* **124**, 1985, 149.
- Bennett J. M., Catovsky D., Daniel M. T. et al.: Proposal for classification of the myelodysplastic syndromes. *Brit. J. Haematol.* **51**, 1982, 189.
- Benz C., Silverberg M., Cadman E.: Use of high-dose oral methotrexate sequenced at 24 hours with 5-fluorouracil. *Cancer Treat. Rep.* **67**, 1983, 297.
- Berk P. D., Goldberg J. P., Donovan P. B. et al.: Therapeutic recommendation in polycythemia vera based on polycythemia vera study group protocol. *Semin. Hematol.* **23**, 1986, 132.
- Berdel F. W., Bausert W. R. E., Fink U. et al.: Anti-tumor action of alkyl-lysophospholipids (Review). *Anticancer Res.* **1**, 1981, 345.
- Berman M. L.: Prognosis and treatment of endometrial carcinoma. *Amer. J. Obstet. Gynecol.* **130**, 1980, 697.
- Bergman U., Wahba A. H., Grimeson T. (Eds.): *Studies in drug utilisation*. World Health Organisation, Copenhagen 1979.
- Blachley J. D., Hill J. B.: Renal and electrolyte disturbances associated with cis-platin. *Ann. intern. Med.* **95**, 1981, 628.

- Bonadonna G., Rossi A., Valagussa P.: Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. *Lancet I*, 1985, 976.
- Borecký L., Fuchsberger N.: Interferon as therapeutic agent. *Acta virol.* 27, 1983, 359.
- Bonnetterre J., Peyrat J. P., Vandewalle B. et al.: Prolactin receptors in human breast cancer. *Eur. J. Cancer clin. Oncol.* 18, 1982, 1157.
- Borel J. F., Lafferty K. J.: Cyclosporin: Speculation about its mechanism of action. *Transplant. Proc.* 15, 1983, 1881.
- Brady L. W.: Multimodality therapy: in: Brodsky I. (Ed.): *Cancer chemotherapy III*. Grune & Stratton, New York 1978, s. 1881.
- Braine H. G., Sensenbrenner L. L., Wright S. K. et al.: Bone marrow transplantation with major ABO group incompatibility. *Blood* 60, 1982, 420.
- Bridgen D., Keeny R. E., King H. D.: The present and future for acyclovir. *J. antimicrobial. Chemother.* 12, 1983, Suppl. B, 196.
- Brown B. W.: Statistical controversies in the design of clinical trials. *Controlled clin. Trials* 1, 1980, 13.
- Brugarolaz A., Gosavalez M.: Treatment of cancer by an inducer of reverse transformation. *Lancet I*, 1980, 13.
- Bruning P. F., Bonfrère J. M., Engelsman E. et al.: Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer. *Breast Canc. Res. Treat.* 4, 1984, 289.
- Brusamolino E., Canevari A., Salvaneschi L.: Efficacy trial of pipobroman in essential thrombocythemia. *Cancer Treat. Rep.* 68, 1984, 1339.
- Bryant C.: New chemoprotective agent. *Lancet II*, 1980, 657.
- Budman D. R., Schulman P., Marks M.: Phase I trial of vinzolidine. *Cancer Treat. Rep.* 68, 1984, 979.
- Burkert H.: Ifosfamide. *Semin. Oncol.* 9, Suppl. 1, 1982, 28.
- Byfield J. E., Hornbeck C. L., Frankel S. S.: Relevance of the pharmacology of oral tegafur to its use as a 5-fluorouracil pro-drug. *Cancer Treat. Rep.* 69, 1985, 645.
- Cabanillas F., Burgess M. A., Bodey G. P. et al.: Sequential chemotherapy and late intensification for malignant lymphoma of aggressive histologic type. *Amer. J. Med.* 74, 1983, 382.
- Cadman E. C., Heimer R., Davis L.: Enhanced 5-fluorouracil nucleotide formation following methotrexate. *Science* 205, 1979, 1135.
- Canetta R. M., Carter S. K.: Developing new drugs for ovarian cancer. *J. Cancer Res. Clin. Oncol.* 107, 1984, 111.
- Carlson R. W., Sikic B. I.: Continuous infusion or bolus injection in cancer chemotherapy. *Ann. intern. Med.* 99, 1983, 823.
- Carter S. K.: Clinical trials in cancer chemotherapy. *Cancer* 40, 1977, 544.
- Casper E. S., Gall F. S., Sordillo P. P. et al.: Phase II clinical trials of Galium Nitrate. *Cancer Treat. Rep.* 69, 1985, 1019.
- Clarkson B., Ellis S., Little C. et al.: Acute lymphoblastic leukemia in adults. *Semin. Oncol.* 12, 1985, 160.
- Cohen L. F., Balow J. E., Magrath I. T. et al.: Acute tumor lysis syndrome. *Amer. J. Med.* 68, 1980, 486.
- Cohen P., Wax Y., Modan B.: Seasonality in the occurrence of breast cancer. *Cancer Res.* 43, 1983, 892.
- Constanzi J. J., Fletcher W. S., Balcerzak S. P. et al.: Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. *Cancer* 53, 1984, 833.
- Cornbleet M. A., McElwain T. J., Kumer P. J. et al.: Treatment of advanced malignant melanoma with high-dose melphalan and autologous bone marrow transplantation. *Brit. J. Cancer* 48, 1983, 329.
- Cradock J. C., Kleinman L. M., Rahman A.: Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium and hydrocortisone sodium succinate. *Amer. J. Hosp. Pharm.* 35, 1978, 402.

- Crooke S. T., Strong J. F., Bradner W. T.: Tallysomyacin, a third generation bleomycin analog. s. 83–90 in: Carter S. K. et al. (Eds.): *New drugs in cancer chemotherapy*. Springer-Verlag, Berlin, Heidelberg, New York 1981.
- Cunningham D., McArdie C. S., Carter D. C. et al.: Advanced gastric cancer *Brit. J. Surg.* 71, 1984, 679.
- Curt G. A., Clendenin N. J., Chabner B. A.: Drug resistance in cancer. *Cancer Treat. Rep.* 68, 1984, 87.
- Černý V., Koza I.: Is adjuvant chemotherapy beneficial for treatment of cancer? *Chemotherapia oncologica, VÚKEO, Brno* 1984, s. 11–16.
- Daghestani A. N., Arlin Z. A., Leyland J. N. et al.: Phase I and II clinical and pharmacological study of 4'-demetoxydaunorubicine (Idarubicin) in patients with acute leukemia. *Cancer Res.* 45, 1985, 1408.
- Danova L. A., Triskina Y. A., Geršanovič M. L.: Rezultaty kliničeskovo izučeniija karmimycina. *Vopr. Onkol.* 29, 1983, 46.
- Dérier L.: Rythm and proliferation with special reference to six-day rythm of blood leukocyte count. *Neoplasma* 7, 1960, 117.
- Dicke K. A., Jagannath S., Spitzer G.: The role of autologous bone marrow transplantation in various malignancies. *Semin. Hematol.* 21, 1984, 109.
- Dienstbier Z.: Hodgkin's disease. *Acta Univ. Carol. Monographia* 107, Univerzita Karlova, Praha, 1984.
- Di Marco A.: Epirubicin: Mechanism of action at the cellular level; s. 41–50 in: Bonadonna G. (Ed.): *Advances in anthracycline chemotherapy*. Masson, Milano 1984.
- Donati M. B., Davidson J. F., Garattini S. (Eds.): *Malignancy and the hemostatic system*. Raven Press, New York, 1981.
- Donegan L. W.: Cancer and pregnancy. *Ca-A Cancer J. Clin.* 33, 1983, 194.
- Donner L.: Další pokus o dělení zhoubných nehodgkinských lymfomů. *Vnitřní Lék.* 30, 1984, 472.
- Drews J.: Immunostimulation. *Klin. Wschr.* 62, 1984, 254.
- Driscoll L. S.: The preclinical new drug research program of the National Cancer Institute. *Cancer Treat. Rep.* 68, 1984, 63.
- Dunagin W. G.: Dermatologic toxicity s. 125–154 in: Perry M. C. (Ed.): *Toxicity of chemotherapy*. Grune & Stratton, New York 1984.
- Drobník J.: Antitumor activity of platinum complexes. *Cancer Pharmacol. Chemother.* 10, 1983, 145.
- Dvořák O.: Cytembena treatment of advanced gynaecological carcinomas. *Neoplasma* 18, 1971, 461.
- Eilber F. R., Weisenburger T. H.: Soft-tissue sarcomas; s. 636–634 in: Haskel C. M. (Ed.): *Cancer treatment*, W. B. Saunders, Philadelphia 1985.
- Einhorn L. H., Donohane J. P.: Combination chemotherapy in disseminated testicular cancer. *Semin. Oncol.* 6, 1979, 81.
- Elis J., Heinige A.: Klinické zkoušení nových léků s protinádorovým účinkem; s. 27–36. in: *Klinické zkoušení cytostatik, Léčiva, Praha* 1981.
- Ensminger W. D., Gyves J. W.: Regional cancer chemotherapy. *Cancer Treat. Rep.* 67, 1984, 101.
- Erslev A. J.: Chemotherapy and erythropoiesis; s. 287–295 in: Brodsky I. (Ed.): *Cancer chemotherapy III*. Grune & Stratton, New York, 1978.
- Esterhay J. R., Aisner J., Levi J. A. et al.: High-dose 6-merkaptopurin in advanced refractory cancer. *Cancer Treat. Rep.* 62, 1978, 1229.
- Evans C. H., Ransom J. H., Heinbaugh J. A.: Leukoregulin, a molecular mediator of natural killer cell cytotoxicity. *Proc. Amer. Assoc. Cancer Res.* 25, 1984, 268.
- Feun L. G., Wallace S., Stewart D. J. et al.: Intracarotid infusion of cis-DDP in the treatment of recurrent malignant brain tumors. *Cancer* 54, 1984, 794.
- Fialkow P. J., Jacobson R. J., Papayannopoulos T.: Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. *J. clin. Invest.* 62, 1978, 815.

- Fidler I. J., Poste G.: The cellular heterogeneity of malignant neoplasms: Implication for adjuvant chemotherapy. *Semin. Oncol.* 12, 1985, 207.
- Flodgren P., Borgstrom S., Jonsson T. et al.: Metastatic malignant melanoma: Regression induced by combined treatment with interferon and cimetidine. *Int. J. Cancer* 32, 1983, 657.
- Folkman J.: Angiogenesis and its inhibitors; s. 42–63 in: De Vita V. T., Hellman S., Rosenberg S. A. (Eds.): Important advances in oncology 1985, J. B. Lippincott Comp., Philadelphia 1985.
- Foon K. A., Billing R. J., Teraski P. I. et al.: Immunological classification of acute lymphoblastic leukaemia. Implications for normal lymphoid differentiation. *Blood* 46, 1980, 1120.
- Foon K. A., Gale R. P.: Controversies in the therapy of acute myelogenous leukemia. *Amer. J. Med.* 72, 1982, 963.
- Foon K. A., Sherwin S. A., Abrams P. G. et al.: Treatment of advanced non-Hodgkin's lymphoma with recombinant leukocyte A interferon. *New Engl. J. Med.* 311, 1984, 1148.
- Fox B.: Vinca alkaloids. *Cancer Topics* 5, 1984, 26.
- Fraschini G., Yap H. Y., Hortobagnyi J. et al.: Five-day continuous infusion of vinblastine in the treatment of breast cancer. *Cancer* 56, 1985, 225.
- Frei E., Teicher B., Rosowsky A.: Principles of adjuvant chemotherapy; ss. 61–70 in: Jones S. E., Salmon S. E. (Eds.): Adjuvant therapy of cancer IV, Grune & Stratton, Orlando 1984.
- Fremuth F.: Chalcones and specific growth factors in normal and tumour growth. *Acta Univ. Carol., Monogr.* 110, Univerzita Karlova, Praha, 1984.
- Frytak S., Moertel C. G., Schutt A. et al.: A phase I study of cytembena. *Cancer* 37, 1976, 1248.
- Furr B. J. A., Jordan V. C.: The pharmacology and clinical uses of tamoxifen. *Pharm. Ther.* 25, 1984, 127.
- Gallo R. C., Salahudin S. Z., Popovic M.: Frequent detection and isolation of cytopathic retrovirus (HTLV III) from patients with AIDS. *Science* 224, 1984, 500.
- Gambrell R. D., Bagnell C. A., Greenblatt R. B.: Role of estrogens in the etiology and prevention of endometrial cancer. *Amer. J. Obstet. Gynec.* 146, 1983, 696.
- Gehan E. A., Freireich E.: Cancer clinical trials. *Semin. Oncol.* 8, 1981, 430.
- Gell P. J. G., Coombs R. R. A.: Clinical aspects of immunology. Blackwell Scientific Publications, Oxford 1975.
- Ginsberg S. J., Comis R. L.: The pulmonary toxicity of antineoplastic agents; s. 227–268 in: Perry M. C. (Ed.): Toxicity of chemotherapy. Grune & Stratton, New York 1984.
- Gifford R. P. M., Ferguson R. M., Voss B. V.: Cimetidin reduction of tumour formation in mice. *Lancet* I, 1981, 638.
- Gilchrist N. L., Cunningham D., Cowan R. A.: Vitamin D₃: Phase I study in low grade non-Hodgkin's lymphoma. *Brit. J. Cancer* 51, 1985, 589.
- Giralt E., Jouve M., Palangie T. et al.: Cancer du sein metastase. *Bull. Cancer* 71, 1984, 22.
- Gold E. J., Martlesman R. H., Itri L. M. et al.: Phase I clinical trial of 13-cis-retinoid acid in myelodysplastic syndromes. *Cancer Treat. Rep.* 67, 1983, 981.
- Goldie J. H., Coldman A. J.: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. *Cancer Treat. Rep.* 63, 1979, 1727.
- Goldie J. H., Coldman A. J.: Genetic instability in the development of drug resistance. *Semin. Oncol.* 12, 1985, 222.
- Gorin N. C., Dousy L., Laporte J. P. et al.: Autologous bone marrow transplantation using marrow incubated with Asta Z 7557 in adult acute leukemia. *Blood* 67, 1986, 1376.
- Gray D. P., Grever M. R., Siaw M. F. E. et al.: 2'-deoxycoformycin and 9-beta D arabi-

- nofuranosyladenine in the treatment of refractory acute myelocytic leukemia. *Cancer Treat. Rep.* **66**, 1982, 253.
- Greco A. F., Johnson D. H., Hinshworth J. D. et al.: Chemotherapy of small-cell lung cancer. *Semin. Oncol.* **12**, Suppl. 6, 1985, 28.
- Green S. B.: Randomized clinical trials. *Semin. Oncol.* **9**, 1981, 417.
- Grever M. R., Bisaccia E.: An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. *Blood* **61**, 1983, 279.
- Gurtoo H. L., Marinello A. J., Berrigan M. J.: Effect of thiols on toxicity and carcinostatic activity of cyclophosphamide. *Semin. Oncol.* **10**, 1983, 35.
- Hacker M., Douple E., Krakoff I. (Eds.): Platinum coordination complexes in cancer chemotherapy. Martinez-Nijhof Publish., Amsterdam 1984.
- Hamburger A. W., Salmon S. E.: Primary bioassay on human tumor stem cells *Science* **197**, 1977, 846.
- Hahn D. A.: Hexamethylmelamin and pentamethylmelamine: An update. *Drug. Intell. Clin. Pharm.* **17**, 1983, 418.
- Hampl R., Kimlová I., Stárka L.: Stanovení estrogenních receptorů v nádorových tkáních. Možnosti a omezení. *Čas. Lék. čes.* **121**, 1982, 1288.
- Hanks G. W.: Corticosteroids in terminal cancer. *Postgrad. Med. J.* **59**, 1983, 702.
- Harris A. L.: Intercalating agents. *Cancer Topics* **4**, 1984, 134.
- Harris J. R., Hellman S.: Limited surgery and radiation as primary local treatment for carcinoma of the breast; s. 243–253 in: De Vita (Ed.): *Important advances in oncology 1985*, Lippincott, Philadelphia 1985.
- Hartley-Asp B.: Estramustin-induced mitotic arrest in two human prostatic carcinoma cell lines. *Prostate* **5**, 1984, 93.
- Haskel C. M.: *Cancer treatment*, W. B. Saunders, Philadelphia 1985.
- Haškovcová H., Lukášová M.: Psychické a lidské problémy nemocných s akutní leukémií na jednotce intenzivní hematologické péče. *Prakt. Lék.* **61**, 1981, 715.
- Haus E., Halberg F., Scheving L. E.: Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system. *Science* **177**, 1972, 80.
- Head D. R., Savage R. A., Cerezo L. et al.: Reproducibility of the French-American-British classification of acute leukemia. *Amer. J. Hemat.* **19**, 1985, 47.
- Herman E. H., Witiak D. T., Hellmann K. et al.: Biological properties of ICRF 159 and related compounds. *Adv. Pharmacol. Chemother.* **19**, 1982, 249.
- Herrera Ornelas L., Abraham F.: Intravenous injection of a hematoporphyrin derivative for photoradiation therapy. *Clin. Res.* **33**, 1985, 452.
- Hillcoat B. L., Levi J., Snyder R.: Preparation and administration of antineoplastic agents. *Med. J. Austr.* **22**, 1983, 424.
- Hoffman P. C., Bitran J. D., Golomb H. M.: Chemotherapy of metastatic non-small cell bronchogenic carcinoma. *Semin. Oncol.* **10**, 1983, 111.
- Holland Jimmie: Psychologic aspects of cancer. s. 991–1021 in: Holland J. F., Frei E. (Eds.): *Cancer medicine*. Lea & Febiger, Philadelphia 1982.
- Holoye P. Y., Duelge J., Hansen R. M. et al.: Prophylaxis of ifosfamide toxicity with oral acetylcystein. *Semin. Oncol.* **10**, 1983, 66.
- Honn K. V., Busse W. D., Sloane B. F.: Prostacyclin and thromboxanes. Their role in tumor cell metastasis, *Biochem. Pharmacol.* **32**, 1983, 1.
- Horton J., Hill G. J.: *Klinická onkologie. Z anglického originálu Clinical oncology vydaného nakl. W. B. Saunders, Philadelphia 1977 vydalo Avicenum, Praha 1982.*
- Howard N., Stenner R. W.: An improved „ice cap“ to prevent alopecia caused by adriamycin. *Brit. J. Radiol.* **56**, 1983, 963.
- Howell S. B., Pfeifle C. L., Wung W. E.: Intraperitoneal cisplatin with systemic thiosulphate protection. *Ann. intern. Med.* **97**, 1982, 845.
- Hrodek O., Veselý J.: 5-azacytidin in childhood leukemia. *Neoplasma* **18**, 1971, 493.
- Hrushesky W. J. M.: Chemotherapy timing s. 449–477 in: Perry M. C. (Ed.): *Toxicity of chemotherapy*. Grune & Stratton, New York 1984.

- Chang J., Morgenstern G., Deakin D. et al.: Reconstitution of haemopoietic system with autologous marrow taken during relapse of acute myeloblastic leukaemia and grown in long-term culture. *Lancet I*, 1981, 1986, 175.
- Chapman R. M.: Effect of cytotoxic therapy on sexuality and gonadal function. *Semin. Oncol.* 9, 1982, 84.
- Ihde D. C.: Current status of therapy for small cell carcinoma of the lung. *Cancer* 54, 1984, 2722.
- Ikic D., Krusic J., Kirchmajer C. et al.: Application of human leukocyte interferon in patients with carcinoma of uterine cervix. *Lancet I*, 1981, 1027.
- Ise T., Ohtsuki H., Akatsuka J. et al.: Clinical study of cycloctidine in children with acute leukemia. *Jap. J. clin. Oncol.* 6, 1976, 1.
- Jacquillat C., Baillet F., Blondon J. et al.: Neoadjuvant chemotherapy of breast cancer. *Drugs exp. clin. Res.* 12, 1986, 147.
- Jagannath S., Spitzer G., Dicke K. A. et al.: High dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease. *Proc. Amer. Soc. clin. Oncol.* 20th meet., 1984, 252.
- Jain K., Langleben A., Gulati S.: In vitro chemopurification of bone marrow. *Proc. Amer. Assoc. Cancer Res.* 74th Meet, 1983, 316.
- Jones P., Taylor S. M.: Cellular differentiation. *Cell* 20, 1980, 85.
- Jones R. B., Frank R., Maas T.: Safe handling of chemotherapeutic agents. *Ca-A Cancer J. Clin.* 33, 1983, 258.
- Jos W. M., Van der Meer H.: Infection in bone marrow transplant recipient. *Semin. Hematol.* 11, 1984, 123.
- Juret P., Heron J. F., Couette J. E. et al.: Hydroxy-9-methyl-2-ellipticinum for osseous metastases for breast cancer. *Cancer Treat. Rep.* 66, 1982, 1909.
- Kantarjian H., Dreicer R., Barlogie B. et al.: High-dose cytosine arabinoside in multiple myeloma. *Europ. J. Cancer clin. Oncol.* 20, 1984, 227.
- Karmali R. A.: Prostaglandins and cancer. *Ca-A Cancer J. Clin.* 33, 1983, 322.
- Kavanagh J., Wallace S., Delclos L. et al.: Update of the results of intra-arterial chemotherapy for advanced squamous cell carcinoma of the cervix. *Proc. Amer. Soc. clin. Oncol.* 20th meet., 1984, 172.
- Kelsen D.: Chemotherapy of esophageal cancer. *Semin. Oncol.* 11, 1984, 159.
- Kempin S., Lee B. J., Thaler H. T. et al.: Combination chemotherapy of advanced chronic lymphocytic leukemia. *Blood* 60, 1982, 1110.
- Kennedy B. J.: Combination versus successive single agent chemotherapy in lymphocytic lymphoma. *Cancer* 41, 1978, 23.
- Kessler J. F., Meyskens F. L., Levine N. et al.: Treatment of cutaneous T-cell lymphoma with 13-cis-retinoic acid. *Lancet I*, 1983, 1345.
- Klener P., Donner L., Hynčiča V.: Possible mechanism of vinblastine-induced thrombocytosis. *Scand. J. Haematol.* 12, 1974, 179.
- Klener P., Bubeník J., Donner L.: Influence of heparine and defibrase on the growth of malignant tumours. *Neoplasma* 25, 1978, 631.
- Klener P.: Poznámky k nové hypotéze o vzniku zhoubného bujení a k možnostem jejího léčebného využití. *Prakt. Lék.* 59, 1979a, 850.
- Klener P.: Chemotherapy of haematological malignancies. *Acta Univ. Carol. Medica, Monogr.* 90, Univerzita Karlova, Praha, 1979b.
- Klener P., Němeček K., Donner L.: Hodgkinova choroba a těhotenství. *Čas. Lék. čes.* 120, 1981, 1425.
- Klener P.: Lycurim (NSC 122402) in the treatment of chronic lymphocytic leukemia. *Neoplasma* 29, 1982a, 87.
- Klener P., Hausner P., Donner L.: Management of advanced Hodgkin's disease in remission. *Folia haematol.* 109, 1982b, 213.
- Klener P.: Zásady podpůrné léčby u zhoubných nádorů a hemoblastos. *Avicenum, Praha* 1982c.

- Klener P., Háber J.: Value of prednimustine in treating non-Hodgkin's lymphomas of favourable histological type. *Folia haematol.* 112, 1985a, 103.
- Klener P., Háber J.: Treatment of refractory leukemia with high-dose cytosine arabinoside. *Neoplasma* 32, 1985b, 113.
- Klener P., Lojda Z., Háber J. et al.: Problems with prognostic criteria in patients with chronic lymphocytic leukemia with special references to DPP II assessment. *Neoplasma* 33, 1986, 737.
- Koeffler H. P.: Myelodysplastic syndromes (Preleukemia). *Semin. Hematol.* 23, 1986, 284.
- Kohler G., Milstein C.: Continuous cultures of fused cells secreting antibody of predestined specificity. *Nature* 256, 1975, 495.
- Kofránek I., Matějovský Z., Štibingerová V.: Osteosarkom. Jeho problematika a léčba. *Čas. Lék. čes.* 124, 1985, 486.
- Koutecký J. a spol.: *Nádory dětského věku.* Avicenum, Praha 1978.
- Křepelka J.: Aminokyseliny, jejich deriváty a peptidy v chemoterapii rakoviny. *Čs. Farm.* 32, 1983, 76.
- Kubec V.: Zásady přípravy a aplikace cytostatik. Metodický list hlavního odborníka pro obor radioterapie č. 1, 1983.
- Kummet T., Meyskens F. L.: Vitamin A: Potential inhibitor of human cancer. *Semin. Oncol.* 10, 1983, 281.
- Kvasnička J., Richter J., Pekárek J.: Transfer faktor. *Čas. Lék. čes.* 119, 1980, 1427.
- Labrie F., Belanger A., Dupont A. et al.: Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. *Lancet* II, 1984, 1090.
- Lawrence H. J., Reis C. A.: AMSA — a promising new agent in refractory acute leukemia. *Cancer Treat. Rep.* 66, 1982, 1475.
- Le Chevalier T., Smith E. P., Harker P. S.: Chemotherapy and combined modality therapy for locally advanced metastatic gastric carcinoma. *Semin. Oncol.* 12, 1985, 46.
- Lee Y. J., Wesley A.: Statistical contribution to phase II trials in cancer. *Semin. Oncol.* 8, 1981, 403.
- Lenhard R. E., Ordder S. E., Spunberg J. J. et al.: Radioimmunoglobulins: A new therapeutic modality in Hodgkin's disease. *Proc. Amer. Soc. clin. Oncol.* 19th meet., 1983, 211.
- Lennert K.: *Malignant lymphomas other than Hodgkin's disease.* Springer Verlag, Berlin, Heidelberg, New York 1978.
- Levine H. B.: *Ketoconazole in the management of fungal disease.* Adis Press, New York, Tokyo, Sydney 1982.
- Levine A. M., Forman S. J., Meyer P. R. et al.: Successful therapy of convoluted T-lymphoblastic lymphoma in the adult. *Blood* 61, 1983, 92.
- Ley T. J., De Simone J., Noguchi C. et al.: 5-azacytidine selectively increased fetal hemoglobin synthesis in patients with beta-thalassemia and sickle-cell disease. *Blood* 60, Suppl. 1, 1982, 54.
- Lippman M. E., Buzdar A., Tormey D. C.: Combining endocrine and chemotherapy — any true benefit? *Breast Cancer Res. Treat.* 4, 1984, 251.
- Lokich J., Ensminger W.: Ambulatory pump devices for hepatic artery infusion. *Semin. Oncol.* 10, 1983, 193.
- Lotze M. T., Matory Y. L., Ettinghausen S. E. et al.: In vivo administration of purified human interleukin 2. *J. Immunol.* 135, 1985, 2865.
- Lotzová E.: Effector immune mechanism in cancer. *Nat. Immun. Cell Growth Regul.* 4, 1985, 293.
- Lukášová M., Sedláčková M., Chudomel V. et al.: Výsledky léčby nemocných s akutní leukémií na jednotce intenzivní hematologické péče. *Prakt. Lék.* 63, 1983, 918.
- Maeda H.: Neocarzinostatin in cancer chemotherapy (Review). *Anticancer Res.* 1, 1981, 175.

- Magin R. L.: Hyperthermia and chemotherapy. *Europ. J. Cancer clin. Oncol.* **19**, 1983, 1655.
- Málek P.: Vědecké a nevědecké přístupy k hodnocení léčiv; s. 3—13 v: *Klinické hodnocení léčiv*, Léčiva n. p., Praha, 1981.
- Maňka I. a kol.: *Klinická onkologie*. Osveta, Martin, 1979.
- Manzjukova L. V., Platinskij J., Marenich A. F.: Clinical evaluation of antibiotic bleomycin. *Antitumor Ther. Rep.* **10**, 1984, 15.
- Maral R., Mathé G., Dantchev D. et al.: Aclacinomycin A. Present status of experimental and clinical studies. *Drugs exp. Clin. Res.* **9**, 1983, 375.
- Marks P. A., Rifkind R. A.: Differentiation modifiers. *Cancer (Suppl.)* **54**, 1984, 2766.
- Mastrangelo M. J., Berd D., Maguier H. C.: Current condition and prognosis of tumor immunotherapy. *Cancer Treat. Rep.* **68**, 1984, 207.
- Matějovský Z.: Chemotherapy in complex treatment of bone and soft tissue sarcomas. *Oncology* **37**, Suppl. 1, 1980, 77.
- Matějovský Z., Koutecký J., Povýšil C. et al.: Diagnostika a terapie Ewingova sarkomu. *Čas. Lék. čes.* **124**, 1985, 491.
- Mathews J. H., Wood J. K.: Male fertility during chemotherapy for acute leukemia. *New Engl. J. Med* **303**, 1980, 1235.
- McCarthy D., Hibbin J., Matutes E.: 1,25-dihydroxyvitamin D₃ and myelofibrosis. *Lancet* **I**, 1984, 1289.
- McCune C. S.: Immunologic therapies of kidney carcinoma. *Semin. Oncol.* **10**, 1983, 431.
- McElwain H.: High-dose chemotherapy. *Cancer Topics* **4**, 1983, 86.
- Mechl Z., Krejčí K.: Procarbazine in advanced malignant melanoma. *Neoplasma* **33**, 1986, 91.
- Meshad N. W., Ervin T. J., Kufed A. et al.: Phase I trial of combination therapy with PALA and 5-fluorouracil. *Cancer Treat. Rep.* **65**, 1981, 331.
- Millnar J. W., Hunter A. M., Horne N. W.: Intrapleural immunotherapy with corynebacterium parvum in recurrent malignant pleural effusions. *Thorax* **35**, 1980, 856.
- Milsted R. A. V., Tattersall M. H. N.: Cancer chemotherapy — what can we achieve? *Lancet* **I**, 1980, 1343.
- Miura T., Katayama K., Wada T.: Phase I and II study of a new bleomycin analog (pepleomycin); s. 61—82 in: Carter S. K. et al. (Eds.): *New drugs in cancer chemotherapy*. Springer Verlag, Berlin, 1981.
- Miyamoto T.: Effectiveness of a sequential combination of bleomycin and mitomycin C on advanced cervical cancer. *Cancer* **41**, 1978, 403.
- Moertel C. G., Schutt A. J., Hann R. G. et al.: Phase II study of cytembena in advanced colorectal carcinoma *Cancer Chemother. Rep.* **59**, 1975, 581.
- Moertel C. G., Fleming T. R., Creagen E. T. et al.: High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. *N. Engl. J. Med.* **312**, 1985, 137.
- Morales A., Wilson J. L., Pater J. L. et al.: Cytodestructive surgery and systemic bacillus Calmette-Guérin therapy in metastatic renal cancer. *J. Urol.* **127**, 1982, 230.
- Moazzami B., Walt J. D., Boyd N. R. H.: Use of progestogens as adjuvant to surgery in the treatment of stage I adenocarcinoma of the uterine corpus. *Brit. J. Obstet. Gynaec.* **90**, 1983, 178.
- Muellerleile U., Hanrath P., Garbrecht M. et al.: Prevention of anthracycline related cardiomyopathy by verapamil. *Circulation* **66**, 1982, 215.
- Muscato M. S., Perry M. C., Yarbrow J. W.: Chemotherapy of cervical carcinoma. *Semin. Oncol.* **9**, 1982, 373.
- Myers C. E.: The use of intraperitoneal chemotherapy; s. 218—225 in: De Vita V. T. (Ed.): *Important advances in oncology 1985*. J. B. Lippincott, Philadelphia 1985.
- Natale R. B., Gralla R. J., Witters R. E.: Phase II trial of vindesine in patients with small-cell lung carcinoma. *Cancer Treat. Rep.* **65**, 1981, 129.

- Nečas E. et al.: Decreased sensitivity to hydroxyurea and to ^3H thymidine suicide in the middle of the S-phase. *Cell Tissue Kinet.* 14, 1981, 261.
- Neri B., Comparini T., Miliani A.: Protection effect of L-carnitine (Carnitene Sigma) on acute adriamycin and daunomycin cardiotoxicity in cancer patients. *Clin. Trials J.* (London) 20, 1983, 93.
- Neuwirtová R., Štěpán J.: Significance of biochemical monitoring of bone involvement in myeloma. *Internat. Symposium on recent approaches to chronic lymphoproliferative diseases, Praha, 1985, Abstr.* 95.
- Nissen-Myer R., Kjellgren K., Malmio K.: Surgical adjuvant chemotherapy. Results with one short course after mastectomy for breast cancer. *Cancer* 42, 1978, 2088.
- Nováková J., Andrysek O.: Preliminary results with new cytostatic Penberol in ovarian cancer. *Neoplasma* 27, 1980, 77.
- Norton L., Simon R.: Tumor size, sensitivity to therapy and design of treatment schedules. *Cancer Treat. Rep.* 61, 1977, 1307.
- Obrist R., Obrecht J. P.: Die Bedeutung der Hormonrezeptoren bei der Therapie des Mammakarzinoms. *Schweiz. med. Wschr.* 113, 1983, 749.
- O'Dwyer P. J., Marsoni S., Alonso M. T. et al.: 2'-deoxycoformycin. Summary and future directions. *Cancer Treat. Symp.* 68, 1984, 1.
- Old L. J.: Tumor necrosis factor (TNF). *Science* 230, 1985, 630.
- Oldham R. K.: Biologicals and biological response modifiers: fourth modality of cancer treatment. *Cancer Treat. Rep.* 68, 1984, 221.
- Olson K. B.: Léky, zhoubné nádory a šarlatáni; s. 189 – 198 v: Horton J. Hill G. J. (Eds.): *Klinická onkologie. Vydalo Avicenum, Praha 1982.*
- Osborne C. K., Von Hoff D. D., Cowan J. D. et al.: Bisantrone, an active drug in patients with advanced breast cancer. *Cancer Treat. Rep.* 68, 1984, 357.
- Ovejera A. A., Houchens D. P.: Human tumor xenografts in athymic nude mice as a preclinical screen for anticancer agents. *Semin. Oncol.* 9, 1981, 386.
- Ozols R. F., Young R. C.: Chemotherapy of ovarian cancer. *Semin. Oncol.* 11, 1984, 251.
- Pacagnella A., Tredese F., Salvango L.: Peptichemio in pretreated patients with ovarian cancer. *Cancer Treat. Rep.* 69, 1985, 17.
- Patera J.: Hypertermie v onkologii. *Prakt. Lék.* 63, 1983, 121.
- Perevodčikova N., Buchov M. B., Auseker B. V.: Adriamycin v kombinovanej chemoterapii. *Antibiotiki* 28, 1983, 628.
- Persky L., deKernion J.: Carcinoma of the penis. *Ca-A Cancer J. Clin.* 36, 1986, 258.
- Pettersen E. O., Lindmo T.: Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia. *Brit. J. Cancer* 48, 1983, 809.
- Piguet H., Monconduit M., Tilly F. et al.: Effectiveness of "Chop" regimen in advanced untreated chronic lymphocytic leukemia. *Lancet I*, 1986, 1346.
- Piver M. S., Barlow J. J., Vongtama V. et al.: Hydroxyurea: A radiation potentiator in carcinoma of the uterine cervix. *Amer. J. Obstet. Gynec.* 147, 1983, 803.
- Plank L., Beseda A., Plank J.: Farebný atlas maligných lymfómov. Vyd. Osveta, Martin, 1983.
- Planting A. S. T., Figush J., Blonk J.: Tamoxifen therapy in premenopausal women with metastatic breast cancer. *Cancer Treat. Rep.* 69, 1985, 363.
- Poirer L. A.: Vitamin B₁₂ acceleration of hepatocarcinogenesis. *Proc. Amer. Assoc. Cancer Res.* 15, 1974, 51.
- Poster D. S., Brunos A., Penta J.: Acivicin – an antitumor antibiotic. *Cancer Clin. Trials* 4, 1981, 327.
- Postmus P. E., Mulder N. H., Sleifer D. T.: High-dose etoposide for refractory malignancies. *Cancer Treat. Rep.* 68, 1984, 1471.
- Powels T. J., Ford H. T., Ashley S. et al.: Treatment of disseminated breast cancer with tamoxifen, aminogluthethimide, hydrocortisone, and danazol, used in combination or sequentially. *Lancet I*, 1984, 1369.
- Prokop O.: Lékařské vědy proti pověrám a šarlatánství. Z německého originálu vydaného

- nakladatelství VEB Gustav Fischer Verlag, Jena 1977, vydalo Avicenum, Praha 1984.
- Ramming K. P., Haskell C. M.: Colorectal malignancies; s. 275—307 in: Haskell C. M. (Ed.): Cancer treatment. W. B. Saunders, Philadelphia 1985.
- Ratain M. J., Golomb H. M., Vardiman J. W. et al.: Rapid responses in advanced hairy cell leukemia (HCL) with recombinant alpha-2-interferon (IFN). *Clin. Res.* 32, 1984, 789.
- Reggev A., Kim J. D., Kassarov L. et al.: Method for safe administration of massive (50 grams) doses of methotrexate with equimolar citrovorum factor rescue. *Proc. Amer. Soc. clin. Oncol.* 20th meet., 1984, 33.
- Riggs C. E.: Clinical pharmacology of daunorubicin in patients with acute leukemia. *Semin. Oncol.* 11, Suppl. 3, 1984, 2.
- Rivard G. E., Momparler R., Demers J. et al.: Phase I study of 5-aza-2'-deoxycytidine in children with acute leukemia. *Leukemia Res.* 5, 1981, 453.
- Roberts S. M., Scheinmann F.: New synthetic routes to prostaglandins and thromboxanes. Academic Press, London 1982.
- Rose C., Mourisden H. T.: Combined cytotoxic and endocrine therapy in breast cancer; s. 269 in: Bresciani F. (Ed): Progress in cancer research and therapy, vol. 31, Raven Press, New York 1984.
- Rose C., Thorpe S. M., Andersen K. W. et al.: Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high oestrogen receptor values. *Lancet* I, 1985, 16.
- Rosen G., Suvanisirikul S., Kwon C. et al.: High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma. *Cancer* 33, 1974, 1151.
- Rosen G., Marcove R. C., Caparros B. et al.: Primary osteogenic sarcoma. The rationale for preoperative chemotherapy and delayed surgery. *Cancer* 43, 1979, 2163.
- Rosen S. T., Maciorowski Z., Wittlin F. et al.: Estrogen receptor analysis in chronic lymphocytic leukemia. *Blood* 62, 1983, 996.
- Rosenberg S. A.: Adjuvant chemotherapy of adult patients with soft tissue sarcomas; s. 273-294 in: De Vita V. T. (Ed.): Important advances in oncology 1985. J. B. Lippincott Comp., Philadelphia 1985.
- Roth Z. a spol.: Statistické metody v experimentální medicíně. SZdN, Praha, 1962.
- Rosenzweig M., Dodion P., Brunsch U. et al.: Combination chemotherapy with cisplatin, methotrexate, bleomycin, and vincristin (CABO) in advanced squamous cell carcinoma of head and neck. *Cancer* 54, 1984, 1499.
- Rossleigh M. A., Smith J., Straus D. et al.: Osteonecrosis in patients with malignant lymphoma. *Cancer* 58, 1986, 1112.
- Rubin P.: Late effects of chemotherapy and radiation therapy; a new hypothesis. *Int. J. Radiat. Oncol. Biol. Phys.* 10, 1984, 5.
- Řežábek K., Matějovský E.: Čím přispívá preklinický výzkum nového cytostatika k jeho klinickému hodnocení; s. 14—21 in: Klinické hodnocení cytostatik. Léčiva n. p., Praha 1981.
- Sakalová A. a kol.: Generalizovaný plazmocytóm. Veda — SAV, Bratislava 1983.
- Salmon S. E., Von Hoff D. D.: In vitro evaluation of anticancer drugs with human tumor stem cell assay. *Semin. Oncol.* 8, 1981, 377.
- Samson M. K., Rivkin S. E., Jones S. E. et al.: Dose-response and dose-survival advantage for high versus low dose cisplatin combined with vinblastin and bleomycin in disseminated testicular cancer. *Cancer* 63, 1984, 1029.
- Saurat J. H. (Ed): Retinoids: New trends in research and therapy. Karger A. G., Basel 1985.
- Selby P., Powels R., Robinson B. et al.: High-dose melphalan in multiple myeloma. *Brit. J. Cancer* 50, 1984, 247.
- Sentis H. J., Willemze R., Sloten W. A.: Polychemotherapy in advanced mycosis fungoides. *Brit. J. Dermatol.* 112, 1985, 232.
- Schiffer C. A., De Bellis R., Kasdorf H. et al.: Treatment of blast cell crisis of chronic

- myelogenous leukemia with 5-azacytidin and VP-16 213. *Cancer Treat. Rep.* 66, 1982, 267.
- Schilsky R. L.: Hydroxyurea and cytosine arabinoside: A biochemically rational treatment effective in non-Hodgkin's lymphomas. *Clin. Res.* 32, 1984, 422.
- Schuller D. E., Wilson H. E., Smith R. E. et al.: Preoperative reductive chemotherapy for locally advanced carcinoma of the oral cavity, oropharynx, and hypopharynx. *Cancer* 51, 1983, 15.
- Simon R. M.: Design and conduct of clinical trials; s. 198—225 in: De Vita V. T. (Ed.): *Cancer. Principal & Practice of Oncology*. Lippincott Comp., Philadelphia 1982.
- Sogani P. C., Vagiwale M. R., Whitmore W. F.: Experience with flutamide in patients with advanced prostatic cancer. *Cancer* 54, 1984, 744.
- Smith E. P., Hoth D. F., Levin B. et al.: 5-fluorouracil, adriamycin, and mitomycin C (FAM) chemotherapy in advanced adenocarcinoma of the pancreas. *Cancer* 46, 1980, 2014.
- Smith I. E.: Mitoxantrone (novantrone). A review of experimental and early clinical studies. *Cancer Treat. Rev.* 10, 1983, 103.
- Smith I. E., Harland S. J., Evans B. P.: Carboplatin: A very active new cisplatin analog in the treatment of small cell lung cancer. *Cancer Treat. Rep.* 69, 1985, 43.
- Smith J. A., Middleton R. G.: Incidence and duration of clinical response in prostate cancer patients treated with LHRH analogue. *J. Urol.* 133, 1985, 153.
- Smithers D. W.: On some general concepts in oncology with special reference to Hodgkin's disease. *Int. J. Radiat. Oncol. Biol. Phys.* 9, 1983, 731.
- Soloway M. S.: Rationale for intensive intravesical chemotherapy for superficial bladder cancer. *J. Urol.* 123, 1980, 461.
- Spiegel R. J.: Intron A (interferon alfa-2b): clinical overview. *Cancer Treat. Rev.* 12, 1985, Suppl. B, 5.
- Spiers A. S. D., De Vita D. F., Allar M. J. et al.: Beneficial effects of anabolic steroid during cytotoxic chemotherapy for metastatic cancer. *J. Med.* 12, 1981, 433.
- Spiers A. S. D.: Experience with 2'-deoxycytosine in the treatment of refractory leukemia and lymphoma. *Cancer Treat. Symp.* 2, 1984, 51.
- Stewart A. F.: Therapy of malignancy-associated hypercalcemia. *Amer. J. Med.* 74, 1983, 475.
- Strnad L.: Použití základních statistických metod v lékařském výzkumu. *Lék. zprávy LFKU* 22, Hradec Králové 1977 (sv. 22).
- Stuart-Harris S. R. C.: Mitoxantrone: A phase II study in the patients with breast carcinoma. *Cancer Chemother. Pharmacol.* 8, 1982, 179.
- Svedersky L. P., Figari I. S., Sugarman B. J. et al.: Enhanced antitumor activity of recombinant IFN-gamma in combination with tumor necrosis factors and chemotherapeutic agents. *Int. J. Immunopharmacol.* 7, 1985, 330.
- Štika L., Elis J.: Definované denní dávky — měřítko pro sledování spotřeby léků. *Čs. Zdravot.* 27, 1979, 512.
- Štika L., Sechser T.: Spotřeba cytostatik v ČSSR v průběhu posledních let; s. 82—98 in: *Klinické hodnocení cytostatik, Léčiva*, Praha 1981.
- Sunkara P. S., Prakash N. J.: Inhibitors of polyamine biosynthesis as antitumor and antimetastatic agents; s. 93—126 in: Sunkara P. (Ed.): *Novel approaches to cancer chemotherapy*. Academic Press, New York 1984.
- Talpaž M., Kantarjian H. M., McCredie K. et al.: Hematological remission and cytogenetic improvement induced by recombinant interferon alpha-A in chronic myelogenous leukemia. *N. Engl. J. Med.* 314, 1986, 1065.
- Tan C. T. C., Hancock C. H., Mondora A. et al.: Phase I study of aziridinybenzoquinone (AZQ) in children with cancer. *Cancer Res.* 44, 1984, 831.
- Tepper J. E., Wood W. C., Chen A. M. et al.: Intraoperative radiotherapy; s. 226—292 in: De Vita V. T. (Ed.): *Important advances in oncology 1985*. J. B. Lippincott Comp., Philadelphia 1985.

- Tisdale M. J.: Tumor and host nutrition. *Cancer Topics* 3, 1982, 113.
- Torti F. M., Wolin E. M., Hannigan J. F. et al.: Lithium carbonate reduces episodes of neutropenic infection in patients receiving chemotherapy for testicular cancer. *Clin. Res.* 32, 1984, 423.
- Trachtenberg J.: Ketoconazole therapy in advanced prostatic cancer. *J. Urol.* 132, 1984, 423.
- Tritton T. R., Yee G.: The anticancer agent adriamycin can be actively cytotoxic without entering cells. *Science* 217, 1982, 248.
- Trouet A., Desprès de Campenere D.: Daunorubicin-DNA and doxorubicin-DNA. A review. *Cancer Chemother. Pharmacol.* 2, 1979, 77.
- Turk J. L., Parker D.: Effect of cyclophosphamide on immunological control mechanism. *Immunol. Rev.* 65, 1982, 99.
- Turbow M. M., Ballon S. C., Sikic B. I. et al.: Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial cancer. *Cancer Treat. Rep.* 69, 1985, 465.
- Uitmann J. E., Karnofsky J. R.: Adjuvant therapy: Principles and state of art. s. 637—658 in: Salmon S. E. (Ed.): *Adjuvant therapy of cancer II*. Grune & Stratton, Orlando, New York 1981.
- Van Sloten Harwood K., Aisner J.: Treatment of chemotherapy extravasation. *Cancer Treat. Rep.* 68, 1984, 939.
- Venditti J. M.: Preclinical drug development. Rationale and method. *Semin. Oncol.* 8, 1981, 349.
- Vesely J., Cihak A.: 5-aza-2'-deoxycytidine: Preclinical studies in mice. *Neoplasma* 27, 1980, 113.
- Vesely J., Piskala A.: Mechanism of action of 1-beta-D-arabinofuranosyl 5-azacytosin and its effect in L-1210 mouse leukemic cells. *Neoplasma* 33, 1986.
- Von Hoff D. D.: Use of daunorubicin in patients with solid tumors. *Semin. Oncol.* 9, Suppl. 3, 1984, 23.
- Vugrin D., Whitmore W. F.: The VAB-6 regimen in the treatment of metastatic seminoma. *Cancer* 53, 1984, 2422.
- Waal R., Clausen K.: Carcinoma of the urinary bladder in patients receiving cyclophosphamide. *New Engl. J. Med.* 293, 1975, 271.
- Wade J. C., Schimpff S. C., Newman K. A. et al.: *Staphylococcus epidermidis*: An increasing cause of infection in patients with granulocytopenia. *Ann. intern. Med.* 97, 1982, 503.
- Walker K. J., Turkes A. O., Turkes A. et al.: Treatment of patients with advanced cancer of the prostate using slow-release (depot) formulation of the LHRH agonist ICI 1186630 (Zoladex). *J. Endocr.* 103, 1984, 51.
- Warrel R. P., Straus D. J., Young C. W.: Combination chemotherapy for patients with relapsed malignant lymphoma using methyl-GAG and teniposid. *Cancer Treat. Rep.* 66, 1982, 1121.
- Waxman J. W.: Gonadal effects of cytotoxic chemotherapy. *Cancer Topics*, 4, 1983, 58.
- Webb H. E., Oaten S. W., Pike C. P.: Treatment of malignant ascitic and pleural effusions with *Corynebacterium parvum*. *Brit. med. J.* I. 1978, 338.
- Wedelin C., Bjorkholm M., Biberfeld P. et al.: Prognostic factors in Hodgkin's disease with special reference to age. *Cancer* 53, 1984, 1202.
- Weinstein J. N.: Liposomes as drug carriers in cancer therapy. *Cancer Treat. Rep.* 69, 1984, 127.
- Weiss B. R.: Streptozotocin: A review of its pharmacology, efficacy and toxicity. *Cancer Treat. Rep.* 66, 1982, 427.
- Wenke M., Mráz M., Hynie S.: *Farmakologie*. Avicenum, Praha 1983.
- Welsh J., Stuart J. F. B., Soukop M. et al.: The pharmacokinetics of oral and i. v. treosulfan. *Brit. J. Cancer* 46, 1982, 467.
- Wheeler R. H., Baker S. R.: Single agent and combination drug regional chemotherapy

- for head and neck cancer using an implantable infusion pump. *Cancer* 54, 1984, 1504.
- World Health Organisation: Handbook reporting results of cancer treatment. Geneva, 1979.
- Widder K. J., Senyei A. E.: Magnetic microspheres: A vehicle for selective targeting of drugs. *Pharmacol. Ther.* 20, 1983, 377.
- Wilczek H.: Význam vitamínu D u některých nádorů. *Čas. Lék. čes.* 122, 1983, 129.
- Williams G.: Ketoconazole for prostate cancer. *Lancet* II, 1984, 696
- Willox J. C., Vorr J., Shaw J. et al.: Prednisolone as appetite stimulant in patients with cancer. *Brit. med. J.* 288, 1984, 27.
- Wilson C. B., Gutin P. H.: New therapeutic approaches for brain tumors. *Cancer* 54, 1984, 2702.
- Wisch J. S., Griffin J. D., Kufe D. W.: Response of preleukemic syndromes to continuous infusion of low dose cytarabine. *New Engl. J. Med.* 309, 1983, 1599.
- Workman P.: New drugs against hypoxic cells. *Cancer Topics* 4, 1983, 42.
- Yap H. Y., Yap B. S., Blumenschein G. R. et al.: Bisantrene, an active new drug in the treatment of metastatic breast cancer. *Cancer Res.* 43, 1983, 1402.
- Yarchoran R., Klecker R. W., Weinhold K. J. et al.: Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV III/LAV replication, to patients with AIDS or AIDS-related complex. *Lancet* I, 1986, 575.
- Yuhas J. M.: WR-2721 — a radio and chemoprotective drug of potential clinical value. *Cancer Res.* 40, 1980, 1519.
- Zadra J., Duffy P., Trachtenberg J.: The treatment of metastatic prostatic cancer with ketoconazole. *J. Urol.* 133, 1985, 373.
- Zámečník J., Mlejnecká V.: Sequential and concomittant combination of radiotherapy and chemotherapy; s. 194—196 in: *Chemotherapia oncologica*. VÚKEO, Brno 1984.
- Zvara V., Ďurkovský J., Černý V.: Diagnostika a léčba germinativních nádorů testis. *Prakt. Lék.* 63, 1983, 981.
- Zubrod G. G.: Historic milestone in curative chemotherapy. *Semin. Oncol.* 6, 1979, 490.
- Další literatura u autora.